Portretten voor de website van Crucell: corporate managementlid: Arthur Lahr
Arthur Lahr

Chief Executive Officer

Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he was consultant at McKinsey & Company and engineer at Unilever. At present, Mr. Lahr also serves as a member of the supervisory board of Sanquin, the Dutch national plasma and blood product supplier. Mr. Lahr holds a Masters degree in Applied Physics from the University of Delft, The Netherlands, and an MBA from INSEAD, France.

Robbert van Heekeren

Chief Financial Officer

Robbert van Heekeren is Chief Financial Officer of Kiadis Pharma. Before joining Kiadis Pharma he was Executive Director, Head Global Finance & Control at Organon, the former pharmaceutical business unit of AkzoNobel. Mr. Van Heekeren worked for Organon for more than 10 years in various international management positions. Mr. van Heekeren holds a Masters degree in Economics from Tilburg University, The Netherlands, and a Masters degree in Industrial Engineering & Management Science from Eindhoven University of Technology, The Netherlands.

Jan Feijen

Chief Operations Officer

Jan Feijen is Chief Operations Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Vice President Manufacturing and Technical Operations, Platform Lead Vaccines and Advanced Therapies at Janssen (Pharmaceutical Companies of Johnson & Johnson). Prior to that he held various executive and project lead positions at Crucell, Avebe and Gist Brocades. Mr. Feijen holds a Masters degree in Technical Physics from the University of Delft, The Netherlands.

Jeroen Rovers MD PhD

Senior Vice President & Chief Medical Officer

Dr. Jeroen Rovers is Senior Vice President and Chief Medical Officer of Kiadis Pharma. He has more than 15 years of professional experience in clinical development, including conducting clinical trials, within academia and the pharmaceutical industry, among others as Chief Medical Officer at Ceronco Biosciences, VP Medical Affairs at Kiadis Pharma and Director of Clinical Development and Business Development at Organon. Dr. Rovers obtained his PhD at Leiden University, The Netherlands, on the use of light-activated drugs in the treatment of tumors.

Margot Hoppe

General Counsel & Corporate Secretary

Margot Hoppe is General Counsel & Corporate Secretary. She has over 20 years of experience in corporate legal affairs and worked for various biotechnology companies including Gist-Brocades and DSM. Ms. Hoppe has Masters degrees in Law and Political Science from the Erasmus University of Rotterdam, The Netherlands.